非嚢胞性線維症気管支拡張症市場：世界の市場規模、シェア、動向分析、機会、予測レポート、2019-2029年

非嚢胞性線維症気管支拡張症の世界市場規模は2029年までに13億米ドルに達します。

世界の非嚢胞性線維症気管支拡張症市場は、非嚢胞性線維症気管支拡張症の有病率の上昇、世界人口の急速な高齢化と呼吸器疾患への感受性の高さ、診断技術の継続的な進歩、認知度の向上と早期診断の取り組みにより、活況を呈しています。

戦略コンサルティングおよび市場調査の大手企業であるBlueWeave Consulting社は、最近の調査で、2022年の非嚢胞性線維症気管支拡張症の世界市場規模を9億4,000万米ドルと推定しました。2023年から2029年の予測期間中、世界の非嚢胞性線維症気管支拡張症市場規模はCAGR 5.55％で成長し、2029年には12億9,800万米ドルに達するとBlueWeave社は予測しています。世界の非嚢胞性線維症気管支拡張症市場の主な成長促進要因には、慢性疾患の有病率の増加、ヘルスケア支出の増加、政府のイニシアチブの高まりなどがあります。治療オプションの進歩や、気管支拡張症の症状に関する一般住民や医療専門家の意識の高まりが、早期診断や患者管理の改善につながっています。また、市場の成長は、特に新興経済圏における医療支出の増加の影響を顕著に受けており、これにより気管支拡張症患者の診断と治療へのアクセスが向上しています。研究開発活動の活発化と新興国市場がもたらす潜在的な機会は、予測期間中の市場開拓をさらに推進すると予想されます。しかし、限られた治療選択肢と疾患特異的治療法の欠如、疾患管理と患者のアドヒアランスにおける課題、治療費とヘルスケア負担の高さが、分析期間中の市場全体の成長を抑制すると予想されます。

本レポートの詳細な分析により、世界の非嚢胞性線維症気管支拡張症市場の成長可能性、今後の動向、統計に関する情報を提供します。また、総市場規模の予測を促進する要因も取り上げています。当レポートは、世界の非嚢胞性線維症気管支拡張症市場における最近の技術動向や、意思決定者が健全な戦略的意思決定を行うための業界洞察を提供することをお約束します。さらに、市場の成長促進要因・課題・競争力についても分析しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の非嚢胞性線維症気管支拡張症市場に関する洞察

• 業界のバリューチェーン分析
• DROC分析
  • 成長の原動力
    • 非嚢胞性線維症気管支拡張症の有病率の増加
    • 人口の高齢化と呼吸器疾患に対する高い罹患率
    • 診断技術の進歩
    • 意識の向上と早期診断への取り組み
  • 抑制要因
    • 限られた治療選択肢と疾患特異的治療法の欠如
    • 疾病管理と患者のアドヒアランスにおける課題
    • 高額な治療費とヘルスケア負担
  • 機会
    • 個別化医療と精密な治療アプローチに対する需要の高まり
    • ヘルスケア費の増加とインフラ開発
  • 課題
    • 複雑な疾患の病態生理学と不均一性
    • 臨床管理ガイドラインに関する合意の欠如
• 技術の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析

第4章 世界の非嚢胞性線維症気管支拡張症市場概要

• 市場規模と金額別予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 治療別
    • 手術
    • 理学療法
    • 予防接種
    • 気道薬物療法
    • 抗生物質
    • その他
  • タイプ別
    • 静脈内
    • オーラル
    • その他
  • 診断別
    • CTスキャン
    • 気管支鏡検査
    • 胸部X線
    • 肺機能
    • 喀痰培養検査
    • 血液検査
    • その他
  • エンドユーザー別
    • 診療所
    • 病院
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋（APAC）
    • ラテンアメリカ（LATAM）
    • 中東およびアフリカ（MEA）

第5章 北米の非嚢胞性線維症気管支拡張症市場

• 市場規模と金額別予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 治療別
  • タイプ別
  • 診断別
  • エンドユーザー別
  • 国別
    • 米国
    • カナダ

第6章 欧州の非嚢胞性線維症気管支拡張症市場

• 市場規模と金額別予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 治療別
  • タイプ別
  • 診断別
  • エンドユーザー別
  • 国別
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • オランダ
    • その他欧州

第7章 アジア太平洋の非嚢胞性線維症気管支拡張症市場

• 市場規模と金額別予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 治療別
  • タイプ別
  • 診断別
  • エンドユーザー別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリアとニュージーランド
    • インドネシア
    • マレーシア
    • シンガポール
    • フィリピン
    • ベトナム
    • APACのその他諸国

第8章 ラテンアメリカの非嚢胞性線維症気管支拡張症市場

• 市場規模と金額別予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 治療別
  • タイプ別
  • 診断別
  • エンドユーザー別
  • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
    • ペルー
    • コロンビア
    • 中南米の残りの地域

第9章 中東およびアフリカの非嚢胞性線維症気管支拡張症市場

• 市場規模と金額別予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 治療別
  • タイプ別
  • 診断別
  • エンドユーザー別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • クウェート
    • 南アフリカ
    • ナイジェリア
    • アルジェリア
    • MEAの残りの部分

第10章 競合情勢

• 主要企業とその製品のリスト
• 世界の非嚢胞性線維症気管支拡張症企業の市場シェア分析、2022年
• 経営パラメータによる競合ベンチマーキング
• 主要な戦略的開発（合併、買収、パートナーシップなど）

第11章 世界の非嚢胞性線維症気管支拡張症市場に対するCOVID-19の影響

第12章 企業プロファイル（会社概要、財務マトリックス、競合情勢、主要な人材、主要な競合、連絡先住所、戦略的展望およびSWOT分析）

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Pfizer Inc.
• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Sunovion Pharmaceuticals Inc.
• Insmed Incorporated
• Bayer AG
• Other Prominent Players

第13章 主要な戦略的推奨事項

第14章 調査手法

Global Non-cystic Fibrosis Bronchiectasis Market Size Set to Touch USD 1.3 Billion by 2029.

Global non-cystic fibrosis bronchiectasis market is flourishing because of the rising prevalence of non-cystic fibrosis bronchiectasis, rapidly aging world population and its higher susceptibility to respiratory diseases, ongoing advancements in diagnostic technologies, and growing awareness and early diagnosis initiatives.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global non-cystic fibrosis bronchiectasis market size at USD 0.94 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global non-cystic fibrosis bronchiectasis market size to grow at a CAGR of 5.55% reaching a value of USD 1.298 billion by 2029. Major growth drivers for the global non-cystic fibrosis bronchiectasis market include an increasing prevalence of chronic diseases, coupled with a rising healthcare expenditure and growing government initiatives. Advancements in treatment options and growing awareness among the general population and healthcare professionals about bronchiectasis symptoms have led to early diagnosis and improved patient management. Also, the market's growth is notably influenced by rising healthcare spending, particularly in emerging economies, which has facilitated better access to diagnosis and treatment for bronchiectasis patients. The rise in research and development activities and the potential opportunities presented by emerging markets are expected to further propel the market's development during the forecast period. However, limited treatment options and lack of disease-specific therapies, challenges in disease management and patient adherence, and the high cost of treatment and healthcare burden are anticipated to restrain the overall market growth during the period in analysis.

Global Non-cystic Fibrosis Bronchiectasis Market - Overview:

The global non-cystic fibrosis bronchiectasis market refers to the worldwide industry involved in the diagnosis, treatment, and management of non-cystic fibrosis bronchiectasis, a chronic respiratory condition. Bronchiectasis is characterized by permanent dilation of the bronchi, leading to recurrent respiratory infections and impaired lung function. Unlike cystic fibrosis-related bronchiectasis, non-cystic fibrosis bronchiectasis is not caused by the genetic disorder cystic fibrosis. The market encompasses various healthcare stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions, all contributing to the development of innovative therapies, medications, and diagnostic tools to address the challenges posed by non-cystic fibrosis bronchiectasis and improve patients' quality of life.

Impact of COVID-19 on Global Non-cystic Fibrosis Bronchiectasis Market:

COVID-19 pandemic adversely affected the global non-cystic fibrosis bronchiectasis market. During the pandemic, healthcare systems were overwhelmed with managing COVID-19 patients, leading to a reduced focus on non-emergency conditions like bronchiectasis. Patients with respiratory conditions faced challenges in accessing healthcare facilities and adhering to treatment regimens due to restrictions and safety concerns. Also, disruptions in the supply chain and clinical trials affected the availability of treatments and research activities. However, with the gradual containment of the pandemic, the market is expected to recover as healthcare systems restore non-emergency services, and efforts to improve respiratory care continue.

Global Non-cystic Fibrosis Bronchiectasis Market - By End User:

On the basis of end user, the global non-cystic fibrosis bronchiectasis market is bifurcated into Clinic and Hospital segments. The hospital segment held a higher market share by end-users. Hospitals are major healthcare centers where patients with respiratory conditions like non-cystic fibrosis bronchiectasis often seek diagnosis, treatment, and management. Hospitals typically have advanced medical facilities, equipment, and specialized healthcare professionals, making them capable of providing comprehensive care for bronchiectasis patients. Also, non-cystic fibrosis bronchiectasis may require specialized diagnostic tests and treatments, such as CT scans, bronchoscopies, and lung function tests, which are readily available in hospitals. The hospital setting also allows for closer monitoring of patients and immediate intervention in case of complications.

Competitive Landscape:

Major players operating in the global non-cystic fibrosis bronchiectasis market include: Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals Inc., Insmed Incorporated, and Bayer AG. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Non-cystic Fibrosis Bronchiectasis Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Non-cystic Fibrosis Bronchiectasis Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Non-cystic Fibrosis Bronchiectasis Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing Prevalence of Non-Cystic Fibrosis Bronchiectasis
    • 3.2.1.2. Aging Population and Higher Susceptibility to Respiratory Diseases
    • 3.2.1.3. Advancements in Diagnostic Technologies
    • 3.2.1.4. Growing Awareness and Early Diagnosis Initiatives
  • 3.2.2. Restraints
    • 3.2.2.1. Limited Treatment Options and Lack of Disease-Specific Therapies
    • 3.2.2.2. Challenges in Disease Management and Patient Adherence
    • 3.2.2.3. High Cost of Treatment and Healthcare Burden
  • 3.2.3. Opportunities
    • 3.2.3.1. Rising Demand for Personalized Medicine and Precision Treatment Approaches
    • 3.2.3.2. Increasing Healthcare Expenditure and Infrastructure Development
  • 3.2.4. Challenges
    • 3.2.4.1. Complex Disease Pathophysiology and Heterogeneity
    • 3.2.4.2. Lack of Consensus on Clinical Management Guidelines
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Non-cystic Fibrosis Bronchiectasis Market Overview

• 4.1. Market Size & Forecast by Value, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment
    • 4.2.1.1. Surgery
    • 4.2.1.2. Physiotherapy
    • 4.2.1.3. Vaccination
    • 4.2.1.4. Airway Pharmacotherapy
    • 4.2.1.5. Antibiotics
    • 4.2.1.6. Others
  • 4.2.2. By Type
    • 4.2.2.1. Intravenous
    • 4.2.2.2. Oral
    • 4.2.2.3. Others
  • 4.2.3. By Diagnosis
    • 4.2.3.1. CT scan
    • 4.2.3.2. Bronchoscopy
    • 4.2.3.3. Chest X-Ray
    • 4.2.3.4. Lung Function
    • 4.2.3.5. Sputum Culture Test
    • 4.2.3.6. Blood Tests
    • 4.2.3.7. Others
  • 4.2.4. By End User
    • 4.2.4.1. Clinic
    • 4.2.4.2. Hospital
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia Pacific (APAC)
    • 4.2.5.4. Latin America (LATAM)
    • 4.2.5.5. Middle East and Africa (MEA)

5. North America Non-cystic Fibrosis Bronchiectasis Market

• 5.1. Market Size & Forecast by Value, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Type
  • 5.2.3. By Diagnosis
  • 5.2.4. By End User
  • 5.2.5. By Country
    • 5.2.5.1. United States
    • 5.2.5.1.1. By Treatment
    • 5.2.5.1.2. By Type
    • 5.2.5.1.3. By Diagnosis
    • 5.2.5.1.4. By End User
    • 5.2.5.2. Canada
    • 5.2.5.2.1. By Treatment
    • 5.2.5.2.2. By Type
    • 5.2.5.2.3. By Diagnosis
    • 5.2.5.2.4. By End User

6. Europe Non-cystic Fibrosis Bronchiectasis Market

• 6.1. Market Size & Forecast by Value, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Type
  • 6.2.3. By Diagnosis
  • 6.2.4. By End User
  • 6.2.5. By Country
    • 6.2.5.1. Germany
    • 6.2.5.1.1. By Treatment
    • 6.2.5.1.2. By Type
    • 6.2.5.1.3. By Diagnosis
    • 6.2.5.1.4. By End User
    • 6.2.5.2. United Kingdom
    • 6.2.5.2.1. By Treatment
    • 6.2.5.2.2. By Type
    • 6.2.5.2.3. By Diagnosis
    • 6.2.5.2.4. By End User
    • 6.2.5.3. Italy
    • 6.2.5.3.1. By Treatment
    • 6.2.5.3.2. By Type
    • 6.2.5.3.3. By Diagnosis
    • 6.2.5.3.4. By End User
    • 6.2.5.4. France
    • 6.2.5.4.1. By Treatment
    • 6.2.5.4.2. By Type
    • 6.2.5.4.3. By Diagnosis
    • 6.2.5.4.4. By End User
    • 6.2.5.5. Spain
    • 6.2.5.5.1. By Treatment
    • 6.2.5.5.2. By Type
    • 6.2.5.5.3. By Diagnosis
    • 6.2.5.5.4. By End User
    • 6.2.5.6. The Netherlands
    • 6.2.5.6.1. By Treatment
    • 6.2.5.6.2. By Type
    • 6.2.5.6.3. By Diagnosis
    • 6.2.5.6.4. By End User
    • 6.2.5.7. Rest of Europe
    • 6.2.5.7.1. By Treatment
    • 6.2.5.7.2. By Type
    • 6.2.5.7.3. By Diagnosis
    • 6.2.5.7.4. By End User

7. Asia-Pacific Non-cystic Fibrosis Bronchiectasis Market

• 7.1. Market Size & Forecast by Value, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Type
  • 7.2.3. By Diagnosis
  • 7.2.4. By End User
  • 7.2.5. By Country
    • 7.2.5.1. China
    • 7.2.5.1.1. By Treatment
    • 7.2.5.1.2. By Type
    • 7.2.5.1.3. By Diagnosis
    • 7.2.5.1.4. By End User
    • 7.2.5.2. India
    • 7.2.5.2.1. By Treatment
    • 7.2.5.2.2. By Type
    • 7.2.5.2.3. By Diagnosis
    • 7.2.5.2.4. By End User
    • 7.2.5.3. Japan
    • 7.2.5.3.1. By Treatment
    • 7.2.5.3.2. By Type
    • 7.2.5.3.3. By Diagnosis
    • 7.2.5.3.4. By End User
    • 7.2.5.4. South Korea
    • 7.2.5.4.1. By Treatment
    • 7.2.5.4.2. By Type
    • 7.2.5.4.3. By Diagnosis
    • 7.2.5.4.4. By End User
    • 7.2.5.5. Australia & New Zealand
    • 7.2.5.5.1. By Treatment
    • 7.2.5.5.2. By Type
    • 7.2.5.5.3. By Diagnosis
    • 7.2.5.5.4. By End User
    • 7.2.5.6. Indonesia
    • 7.2.5.6.1. By Treatment
    • 7.2.5.6.2. By Type
    • 7.2.5.6.3. By Diagnosis
    • 7.2.5.6.4. By End User
    • 7.2.5.7. Malaysia
    • 7.2.5.7.1. By Treatment
    • 7.2.5.7.2. By Type
    • 7.2.5.7.3. By Diagnosis
    • 7.2.5.7.4. By End User
    • 7.2.5.8. Singapore
    • 7.2.5.8.1. By Treatment
    • 7.2.5.8.2. By Type
    • 7.2.5.8.3. By Diagnosis
    • 7.2.5.8.4. By End User
    • 7.2.5.9. Philippines
    • 7.2.5.9.1. By Treatment
    • 7.2.5.9.2. By Type
    • 7.2.5.9.3. By Diagnosis
    • 7.2.5.9.4. By End User
    • 7.2.5.10. Vietnam
    • 7.2.5.10.1. By Treatment
    • 7.2.5.10.2. By Type
    • 7.2.5.10.3. By Diagnosis
    • 7.2.5.10.4. By End User
    • 7.2.5.11. Rest of APAC
    • 7.2.5.11.1. By Treatment
    • 7.2.5.11.2. By Type
    • 7.2.5.11.3. By Diagnosis
    • 7.2.5.11.4. By End User

8. Latin America Non-cystic Fibrosis Bronchiectasis Market

• 8.1. Market Size & Forecast by Value, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Type
  • 8.2.3. By Diagnosis
  • 8.2.4. By End User
  • 8.2.5. By Country
    • 8.2.5.1. Brazil
    • 8.2.5.1.1. By Treatment
    • 8.2.5.1.2. By Type
    • 8.2.5.1.3. By Diagnosis
    • 8.2.5.1.4. By End User
    • 8.2.5.2. Mexico
    • 8.2.5.2.1. By Treatment
    • 8.2.5.2.2. By Type
    • 8.2.5.2.3. By Diagnosis
    • 8.2.5.2.4. By End User
    • 8.2.5.3. Argentina
    • 8.2.5.3.1. By Treatment
    • 8.2.5.3.2. By Type
    • 8.2.5.3.3. By Diagnosis
    • 8.2.5.3.4. By End User
    • 8.2.5.4. Peru
    • 8.2.5.4.1. By Treatment
    • 8.2.5.4.2. By Type
    • 8.2.5.4.3. By Diagnosis
    • 8.2.5.4.4. By End User
    • 8.2.5.4.5.
    • 8.2.5.5. Colombia
    • 8.2.5.5.1. By Treatment
    • 8.2.5.5.2. By Type
    • 8.2.5.5.3. By Diagnosis
    • 8.2.5.5.4. By End User
    • 8.2.5.6. Rest of LATAM
    • 8.2.5.6.1. By Treatment
    • 8.2.5.6.2. By Type
    • 8.2.5.6.3. By Diagnosis
    • 8.2.5.6.4. By End User

9. Middle East & Africa Non-cystic Fibrosis Bronchiectasis Market

• 9.1. Market Size & Forecast by Value, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Type
  • 9.2.3. By Diagnosis
  • 9.2.4. By End User
  • 9.2.5. By Country
    • 9.2.5.1. Saudi Arabia
    • 9.2.5.1.1. By Treatment
    • 9.2.5.1.2. By Type
    • 9.2.5.1.3. By Diagnosis
    • 9.2.5.1.4. By End User
    • 9.2.5.2. UAE
    • 9.2.5.2.1. By Treatment
    • 9.2.5.2.2. By Type
    • 9.2.5.2.3. By Diagnosis
    • 9.2.5.2.4. By End User
    • 9.2.5.3. Qatar
    • 9.2.5.3.1. By Treatment
    • 9.2.5.3.2. By Type
    • 9.2.5.3.3. By Diagnosis
    • 9.2.5.3.4. By End User
    • 9.2.5.4. Kuwait
    • 9.2.5.4.1. By Treatment
    • 9.2.5.4.2. By Type
    • 9.2.5.4.3. By Diagnosis
    • 9.2.5.4.4. By End User
    • 9.2.5.5. South Africa
    • 9.2.5.5.1. By Treatment
    • 9.2.5.5.2. By Type
    • 9.2.5.5.3. By Diagnosis
    • 9.2.5.5.4. By End User
    • 9.2.5.6. Nigeria
    • 9.2.5.6.1. By Treatment
    • 9.2.5.6.2. By Type
    • 9.2.5.6.3. By Diagnosis
    • 9.2.5.6.4. By End User
    • 9.2.5.7. Algeria
    • 9.2.5.7.1. By Treatment
    • 9.2.5.7.2. By Type
    • 9.2.5.7.3. By Diagnosis
    • 9.2.5.7.4. By End User
    • 9.2.5.8. Rest of MEA
    • 9.2.5.8.1. By Treatment
    • 9.2.5.8.2. By Type
    • 9.2.5.8.3. By Diagnosis
    • 9.2.5.8.4. By End User

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Non-cystic Fibrosis Bronchiectasis Company Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Non-cystic Fibrosis Bronchiectasis Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)

• 12.1. Novartis AG
• 12.2. Teva Pharmaceutical Industries Ltd.
• 12.3. Mylan N.V.
• 12.4. Pfizer Inc.
• 12.5. GlaxoSmithKline plc
• 12.6. AstraZeneca plc
• 12.7. Boehringer Ingelheim GmbH
• 12.8. Sunovion Pharmaceuticals Inc.
• 12.9. Insmed Incorporated
• 12.10. Bayer AG
• 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumption & Limitation